Уровень матриксной металлопротеиназы 12 типа в крови больных артериальной гипертонией с высоким сердечно-сосудистым риском на фоне терапии статинами
Вадим Михин,
Валерия Воротынцева,
Тамара Николенко,
Валентина Савельева,
Марина Чернятина,
Николай Громнацкий About the Authors
Вадим Михин
Курский государственный медицинский университет (КГМУ)
Russian Federation
Russian Federation
Валерия Воротынцева
Курский государственный медицинский университет (КГМУ)
Russian Federation
Russian Federation
Тамара Николенко
Курский государственный медицинский университет (КГМУ)
Russian Federation
Russian Federation
Валентина Савельева
Курский государственный медицинский университет (КГМУ)
Russian Federation
Russian Federation
Марина Чернятина
Курский государственный медицинский университет (КГМУ)
Russian Federation
Russian Federation
Николай Громнацкий
Курский государственный медицинский университет (КГМУ)
Russian Federation
Russian Federation
References
1. Tkacheva O.N., Sharashkina N.V., Barabashkina А.V., Novikova I.M., Mishina I.E. Statins in arterial hypertension treatment. Cardiovascular therapy and prevention. 2009;8(7):43-48 (in Russ.). EDN: KYLVOT.
2. Mihin V.P., Osipova O.A., Vorotynceva V.V., Peruckij D.N., Golovina N.I. Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy. Cardiovascular therapy and prevention. 2022;10(21):15-23 (in Russ.). DOI:10.15829/1728-8800-2022-3422. EDN: RBFZXH.
3. Moskalenko MI, Milanova SN, Ponomarenko IV, Polonikov AV, Churnosov MI. Study of associations of polymorphism of matrix metalloproteinases genes with the development of arterial hypertension in men. Kadiologiya. 2019;59(7S):31-39 (in Russ.). DOI: 10.18087/cardio.2598. EDN: AADLDE.
4. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8(3):221-233. DOI: 10.1038/nrm2125.
5. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562-573. DOI: 10.1016/j.cardiores.2005.12.002.
6. Anthony D., George P., Eaton C.B. Cardiac risk factors: biomarkers and genetic tests to determine cardiovascular risk. FP Essent. 2014;421:11-15.
7. Wen D., Du X., Nie S.P., Dong J.Z., Ma C.S. Association between matrix metalloproteinase family gene polymorphisms and ischemic stroke: a meta-analysis. Mol Neurobiol. 2014;50(3):979-985. DOI: 10.1007/s12035-014-8687-8.
8. Luizon M.R., Belo V.A., Fernandes K.S., Andrade V.L., Tanus-Santos J.E., Sandrim V.C. Plasma matrix metalloproteinase-9 levels, MMP-9 gene haplotypes, and cardiovascular risk in obese subjects. Mol Biol Rep. 2016;43(6):463-471. DOI: 10.1007/s11033-016-3993-z.
9. Velho F.M., Cohen C.R., Santos K.G., Silvello D., Martinelli N., Biolo A., Clausell N., Rohde L.E. Polymorphisms of matrix metalloproteinases in systolic heart failure: role on disease susceptibility, phenotypic characteristics, and prognosis. J Card Fail. 2011;17(2):115-121. DOI: 10.1016/j.cardfail.2010.09.017.
10. Moskalenko MI. Associations of polymorphism combinations of matrix metal proteinase with development of essential hypertension. Journal of new medical technologies, eedition. 2017;(2):212-215 (in Russ.). DOI: 10.12737/article_5922bb446cd2bO.14691350. EDN: ZBADTL.
11. Grigorkevich OS, Mokrov GV, Kosova LYu. Matrix metalloproteinases and their inhibitors. Pharmacokinetics and pharmacodynamics. 2019;(2):3-16 (in Russ.). DOI: 10.24411/2587-7836-2019-10040. EDN: BPRQTK.
12. Chen Q., Jin M., Yang F., Zhu J., Xiao Q., Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm. 2013;2013:928315. DOI: 10.1155/2013/928315.
13. Bonnans C., Chou J., Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15(12):786-801. DOI: 10.1038/nrm3904.
14. Hua Y., Song L., Wu N., Xie G., Lu X., Fan X., Meng X., Gu D., et al. Polymorphisms of MMP-2 gene are associated with systolic heart failure prognosis. Clin Chim Acta. 2009;404(2):119-123. DOI: 10.1016/j.cca.2009.03.030.
15. Richardson P.D., Davies M.J., Born G.V. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;2(8669):941-944. DOI: 10.1016/s0140-6736(89)90953-7.
16. Taljaard M., Tuna M., Bennett C., Perez R., Rosella L., Tu J.V., Sanmartin C., Hennessy D., et al. Cardiovascular Disease Population Risk Tool (CVDPoRT): predictive algorithm for assessing CVD risk in the community setting. A study protocol. BMJ Open. 2014;4(10):e006701. DOI: 10.1136/bmjopen-2014-006701.
17. Chen Z.R., Huang B., Fan X.H., Lu H.S., Zhao Z.H., Hui R.T., Yang Y.M., Zhu J., et al. Clinical characteristics and outcomes of patients with acute aortic dissection: impact of hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(3):220-225. (in Chin.). DOI: 10.3760/cma.j.issn.0253-3758.2016.03.007.
18. Markelova E.V., Zdor V.V., Romanchuk A.L., Birko O.N. Matrix metalloproteinases: on their relationship with cytokine system, diagnostic and prognostic potential. Immunopathology, allergology, infectology. 2016; 2: 11-22 (in Russ.). DOI: 10.14427/jipai.2016.2.11. EDN: WEATPT
19. Mihin VP, Vorotynceva VV, Gromnackij NI, Anikin VV. Changes in the elasticity of the vascular wall of arteries and markers of angiopathy on the background of long statin therapy in patients with arterial hypertension with high cardiovascular risk. Kursk Scientific and Practical Bulletin “Man and His Health”. 2020;(4):37-44 (in Russ.). DOI: 10.21626/vestnik/2020-4/05. EDN: DLJVWA.
20. Raffetto J.D., Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75(2):346-359. DOI: 10.1016/j.bcp.2007.07.004.
21. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol. 2001;13(5):534-540. DOI: 10.1016/s0955-0674(00)00248-9.
22. Kolomejchuk S.N., Korneva V.A., Ilyuha V.V., Kuznecova A.S., Kuznecova T.Yu. The study of polymorphic variants of matrix metalloproteinase (MMP-3) gene as a risk marker of arterial hypertension and ischemic heart disease development among the population of the Republic of Karelia. Journal of biomedical technologies. 2014;(2):10-16 (in Russ.). EDN: VASMJT.
23. Freitas-Rodríguez S., Folgueras A.R., López-Otín C. The role of matrix metalloproteinases in aging: Tissue remodeling and beyond. Biochim Biophys Acta Mol Cell Res. 2017;1864(11 Pt A):2015-2025. DOI: 10.1016/j.bbamcr.2017.05.007.
24. Bogdanov LA, Velikanova EA, Shishkova DK, Shabaev AR, Kutihin AG. Neointimal remodeling in carotid atherosclerosis: roles of matrix metalloproteinases-2 and -9 and different phenotypes of vascular smooth muscle cells. Patologicheskaya fiziologiya i eksperimental'naya terapiya. 2020;64(4): 20-30 (in Russ.). DOI: 10.25557/0031-2991.2020.04.20-30. EDN: XUBBZW.
25. He T, Wang J, Wang XL, Deng WS, Sun P. Association between the Matrix Metalloproteinase-9 rs3918242 Polymorphism and Ischemic Stroke Susceptibility: A Meta-Analysis. J Stroke Cerebrovasc Dis. 2017;26(5):1136-1143. DOI: 10.1016/j.jstrokecerebrovasdis.2016.12.036.
26. Lacchini R., Jacob-Ferreira A.L., Luizon M.R., Gasparini S., Ferreira-Sae M.C., Schreiber R., Nadruz W. Jr., Tanus-Santos J.E.Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens. 2012;26(3):171-177. DOI: 10.1038/jhh.2011.8.
27. Abd El-Aziz T.A., Mohamed R.H. Matrix Metalloproteinase 3 Gene Polymorphism and Its Level Predict Morbidity After Acute Myocardial Infarction. Am J Clin Pathol. 2016 ;145(1):134-139. DOI: 10.1093/ajcp/aqv008.
28. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., Albus C., Benlian P., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635-1701. DOI: 10.1093/eurheartj/ehs092.
29. Hoseini S.M., Kalantari A., Afarideh M., Noshad S., Behdadnia A., Nakhjavani M., Esteghamati A. Evaluation of plasma MMP-8, MMP-9 and TIMP-1 identifies candidate cardiometabolic risk marker in metabolic syndrome: results from double-blinded nested case-control study. Metabolism. 2015;64(4):527-538. DOI: 10.1016/j.metabol.2014.12.009.
30. Jormsjö S., Ye S., Moritz J., Walter D.H., Dimmeler S., Zeiher A.M., Henney A., Hamsten A., et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res. 2000;86(9): 998-1003. DOI: 10.1161/01.res.86.9.998.
31. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8(3):221-233. DOI: 10.1038/nrm2125
32. Tanner R.M., Lynch A.I., Brophy V.H., Eckfeldt J.H., Davis B.R., Ford C.E., Boerwinkle E., Arnett D.K. Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension. PLoS One. 2011;6(8):e23609. DOI: 10.1371/journal.pone.0023609.
33. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8): 827-839. DOI: 10.1161/01.RES.0000070112.80711.3D.
34. Levin M., Udi Y., Solomonov I., Sagi I. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects. Biochim Biophys Acta Mol Cell Res. 2017;1864(11 Pt A):1927-1939. DOI: 10.1016/j.bbamcr.2017.06.009.
35. Gavrilyuk N.D., Irtyuga O.B., Druzhkova T.A., Uspenskij V.E., Malashicheva A.B., Kostareva A.A., Moiseeva O.V. Polymorphisms of matrix metalloproteases 2 and 9 genes in ascending aorta aneurism patients.Russian journal of cardiology. 2015;10(126): 65-69 (in Russ.). DOI: 10.15829/1560-4071-2015-10-65-69. EDN: UMADFT.
36. Solov'eva NI. Matrix metalloproteinases and their biological functions. Bioorganicheskaya himiya. 1998;24(4):245-255 (in Russ.). EDN: PAWTSZ.
37. Iyer R.P., Patterson N.L., Zouein F.A., Ma Y., Dive V., de Castro Brás L.E., Lindsey M.L. Early matrix metalloproteinase-12 inhibition worsens post-myocardial infarction cardiac dysfunction by delaying inflammation resolution.Int J Cardiol. 2015;185:198-208. DOI: 10.1016/j.ijcard.2015.03.054.
38. Moskalenko M.I., Polonikov A.V., Sorokina I.N., Yakunchenko T.I., Krikun E.N., Ponomarenko I.V. Gene-environment interactions between polymorphic loci of MMPs and obesity in essential hypertension in women. Problems of endocrinology. 2019;65(6): 425-435 (in Russ.). DOI: 10.14341/probl10236. EDN: UUCTAX.
39. Morris D.R., Biros E., Cronin O., Kuivaniemi H., Golledge J. The association of genetic variants of matrix metalloproteinases with abdominal aortic aneurysm: a systematic review and meta-analysis. Heart. 2014;100(4):295-302. DOI: 10.1136/heartjnl-2013-304129.
Review
For citations:
, , , , , . Humans and their health. 2022;25(4):28-35. (In Russ.)
Views:
222
Email this article 